Literature DB >> 24534601

Obestatin changes proliferation, differentiation and apoptosis of porcine preadipocytes.

Shengqiu Tang1, Xiaoying Dong2, Wei Zhang3.   

Abstract

Obestatin, originally identified and purified from rat stomach extracts, was reported to bind to orphan G protein-coupled receptor, GPR39, and inhibit appetite and gastric motility. This study was conducted to investigate the effects of porcine obestatin on proliferation, differentiation and apoptosis of porcine preadipocytes isolated from subcutaneous fat of piglets. At indicated times of culture, morphology of preadipocytes and accumulated lipid droplets within the cells were identified by invert microscope. After treating with obestatin (0, 0.1, 1, 10 and 100nM), cell proliferation was measured by MTT method and protein expression of CCAAT/enhancer binding protein-α (C/EBPα), peroxisome proliferator-activated receptor-γ (PPARγ), Caspase-7 and Caspase-9 was determined by Western Blot, mRNA expression of GPR39 and Caspase-3 was analyzed by RT-PCR, and the activity of Caspase-3 was measured by spectrophotometric method. The results showed that obestatin had no effect on GPR39 expression, while promotes the optical density (OD) value of cells, enhanced protein expression of PPARγ and C/EBPa, decreased mRNA expression and activity of Caspase-3, and inhibited protein expression of Caspase-7 and Caspase-9 in a dose-dependent manner. These results suggested that obestatin enhances proliferation and differentiation of preadipocytes promoting PPARγ and C/EBPa expression, and inhibiting preadipocyte apoptosis by decreasing expression of Caspase-3, Caspase-7 and Caspase-9.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24534601     DOI: 10.1016/j.ando.2013.10.003

Source DB:  PubMed          Journal:  Ann Endocrinol (Paris)        ISSN: 0003-4266            Impact factor:   2.478


  6 in total

1.  Exposure of pregnant sows to deoxynivalenol during 35-70 days of gestation does not affect pathomorphological and immunohistochemical properties of fetal organs.

Authors:  Wolf Wippermann; Anne Heckmann; Kathrin Jäger; Sven Dänicke; Heinz-Adolf Schoon
Journal:  Mycotoxin Res       Date:  2017-12-29       Impact factor: 3.833

2.  Treatment of lean and diet-induced obesity (DIO) mice with a novel stable obestatin analogue alters plasma metabolite levels as detected by untargeted LC-MS metabolomics.

Authors:  Brian D Green; Stewart F Graham; Elaine Cowan; Praveen Kumar; Kerry J Burch; David J Grieve
Journal:  Metabolomics       Date:  2016-07-05       Impact factor: 4.290

3.  Doxorubicin Inhibits Proliferation of Osteosarcoma Cells Through Upregulation of the Notch Signaling Pathway.

Authors:  Peng Ji; Ling Yu; Wei-Chun Guo; Hong-Jun Mei; Xiao-Ju Wang; Hu Chen; Shuo Fang; Jian Yang
Journal:  Oncol Res       Date:  2014       Impact factor: 5.574

Review 4.  Obestatin as a key regulator of metabolism and cardiovascular function with emerging therapeutic potential for diabetes.

Authors:  Elaine Cowan; Kerry J Burch; Brian D Green; David J Grieve
Journal:  Br J Pharmacol       Date:  2016-05-27       Impact factor: 8.739

Review 5.  The Zinc Sensing Receptor, ZnR/GPR39, in Health and Disease.

Authors:  Michal Hershfinkel
Journal:  Int J Mol Sci       Date:  2018-02-01       Impact factor: 5.923

6.  Small intestinal development in suckling rats after enteral obestatin administration.

Authors:  Monika Słupecka-Ziemilska; Paulina Grzesiak; Michał Jank; Alicja Majewska; Agnieszka Rak; Paweł Kowalczyk; Ikuo Kato; Atsukazu Kuwahara; Jarosław Woliński
Journal:  PLoS One       Date:  2018-10-19       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.